About these reports
Using data from Beacon as of the 16th of January 2023, the following series provides an analysis of the existing oncolytic viruses landscape, an overview of what happened in 2022, and a look at what the future might bring.
The two-part analysis is split into:
- The Current Landscape – An overview of the drug and trial landscape broken down by drug status, highest phase of development, and viral family.
- 2022 in Review – Key highlights of 2022, including collaborations and investments, regulatory designations and, trials started and completed in 2022.
Beacon Oncolytic Viruses
How the most complete oncolytic viruses database can help you
What we cover
Beacon Oncolytic Viruses is a manually curated database solution that includes all publicly available data for preclinical, active, approved, and discontinued virus-based therapies being developed for oncology indications. The database covers:
- Genetically modified or naturally occurring oncolytic virus-based therapies
- Virus based therapeutics including therapeutic viral-vaccines
How Beacon Oncolytic Viruses works
Search the clinical trial and drug landscape by virus type and family, genome types, transgenes, genes deleted or modified for pathway or signalling alteration, envelope modifications, or promoter related modifications, routes of administration, diseases, biomarkers, line of therapy, instantaneously and/or extract the data points you need to conduct more complex analysis.
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated account and research team can help you with questions by showing you how this insight and data is collated on Beacon.